# Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

> **NCT07161193** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Hebei Senlang Biotechnology Inc., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Autoimmune Diseases

## Interventions

- **BIOLOGICAL:** CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT07161193
- **Lead sponsor:** Hebei Senlang Biotechnology Inc., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2027-08-18
- **Final completion:** 2027-11-18
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-09-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07161193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07161193, "Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07161193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*